CEBP Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

Cancer Epidemiology Biomarkers & Prevention 16, 2736-2744, December 1, 2007. doi: 10.1158/1055-9965.EPI-07-0494
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hung, R. J.
Right arrow Articles by Brennan, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hung, R. J.
Right arrow Articles by Brennan, P.

Inherited Predisposition of Lung Cancer: A Hierarchical Modeling Approach to DNA Repair and Cell Cycle Control Pathways

Rayjean J. Hung1,2, Meili Baragatti1,3, Duncan Thomas4, James McKay1, Neonila Szeszenia-Dabrowska5, David Zaridze6, Jolanta Lissowska7, Peter Rudnai8, Eleonora Fabianova9, Dana Mates10, Lenka Foretova11, Vladimir Janout12, Vladimir Bencko13, Amelie Chabrier1, Norman Moullan1, Federico Canzian14, Janet Hall15, Paolo Boffetta1 and Paul Brennan1

1 IARC, Lyon, France; 2 University of California at Berkeley, Berkeley, California; 3 Ecole Nationale de la Statistique et de l'Analyse de l'Information, Bruz, France; 4 Department of Preventive Medicine, University of Southern California, Los Angeles, California; 5 Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland; 6 Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russia; 7 Department of Cancer Epidemiology and Prevention, Cancer Center and Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland; 8 National Institute of Environmental Health, Fodor József National Center for Public Health, Budapest, Hungary; 9 Specialized Institute of Hygiene and Epidemiology, Banska Bystrica, Slovakia; 10 Institute of Public Health, Bucharest, Romania; 11 Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic; 12 Department of Preventive Medicine, Faculty of Medicine, Palacky University, Olomouc, Czech Republic; 13 Charles University of Prague, First Faculty of Medicine, Institute of Hygiene and Epidemiology, Prague, Czech Republic; 14 German Cancer Research Center-Deutsches Krebsforschungszentrum, Heidelberg, Germany; and 15 Institut National de la Sante et de la Recherche Medicale U612, Institute Curie-Recherche, Orsay, France

Requests for reprints: Rayjean J. Hung, IARC, 150 cours Albert Thomas, F-69372 Lyon Cedex 08, France. Phone: 33-4-7273-8023; Fax: 33-4-7273-8342. E-mail: hung{at}iarc.fr

The DNA repair systems maintain the integrity of the human genome and cell cycle checkpoints are a critical component of the cellular response to DNA damage. We hypothesized that genetic variants in DNA repair and cell cycle control pathways will influence the predisposition to lung cancer, and studied 27 variants in 17 DNA repair enzymes and 10 variants in eight cell cycle control genes in 1,604 lung cancer patients and 2,053 controls. To improve the estimation of risks for specific variants, we applied a Bayesian approach in which we allowed the prior knowledge regarding the evolutionary biology and physicochemical properties of the variant to be incorporated into the hierarchical model. Based on the estimation from the hierarchical modeling, subjects who carried OGG1 326C/326C homozygotes, MGMT 143V or 178R, and CHEK2 157I had an odds ratio of lung cancer equal to 1.45 [95% confidence interval (95% CI), 1.05-2.00], 1.18 (95% CI, 1.01-1.40), and 1.58 (95% CI, 1.14-2.17). The association of CHEK2 157I seems to be overestimated in the conventional analysis. Nevertheless, this association seems to be robust in the hierarchical modeling. None of the pathways seem to have a prominent effect. In general, our study supports the notion that sequence variation may explain at least some of the variation of inherited susceptibility. In particular, further investigation of OGG1, MGMT, and CHEK2 focusing on the genetic regions where the present markers are located or the haplotype blocks tightly linked with these markers might be warranted. (Cancer Epidemiol Biomarkers Prev 2007;16(12):2736–44)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2007 by the American Association for Cancer Research.